How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)
Fabrizio Tabbò, Chiara Pisano, Julien Mazières, Laura Mezquita, Ernest Nadal, David Planchard, Anne Pradines, David Santamarı́a, Aurélie Swalduz, Chiara Ambrogio, Silvia Novello, Sandra Ortiz‐Cuaran
Topics & Concepts
TrametinibMedicineDabrafenibV600ELung cancerOncologyClinical trialnon-small cell lung cancer (NSCLC)MEK inhibitorTargeted therapyCancer researchVemurafenibCancerPopulationInternal medicineMutationMAPK/ERK pathwayKinaseGeneBiologyA549 cellGeneticsEnvironmental healthMetastatic melanomaLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysCancer Mechanisms and Therapy